Pharmacogenomic Analysis of Response to Topical Tumor Necrosis Factor α Antagonist Licaminlimab (OCS-02) in Dry Eye Disease [RETRACTED].

A study of patients with dry eye symptoms in the United States found that patients with the CC genotype showed a trend to be more likely to have a partial or complete symptomatic response to topical anti-inflammatory treatment (0.05% cyclosporine or 5% lifitegrast) than patients with the CT or TT genotypes, despite similar baseline symptoms. 42 The CC genotype of rs1800693 is relatively common.

also in 53,322 other papers